Добірка наукової літератури з теми "Vaccine engineering"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Vaccine engineering".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Vaccine engineering"
Rizqoh, Debie. "Genetic Engineering Technique in Virus-Like Particle Vaccine Construction." Jurnal Kesehatan Masyarakat Indonesia 16, no. 4 (December 31, 2021): 203. http://dx.doi.org/10.26714/jkmi.16.4.2021.203-211.
Повний текст джерелаCasiño, Jenny J., and Angelo Mark P. Walag. "Issues and Challenges of, Factors that Affect, and the Primary Influences of Parents’ Decisions to Vaccinate their Adolescents: A Case of a Local National High School in Cagayan de Oro City, Philippines." Canadian Journal of Family and Youth / Le Journal Canadien de Famille et de la Jeunesse 14, no. 1 (January 1, 2022): 147–61. http://dx.doi.org/10.29173/cjfy29752.
Повний текст джерелаSchlotthauer, Felicia, Joey McGregor, and Heidi E. Drummer. "To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity." Viruses 13, no. 5 (April 30, 2021): 805. http://dx.doi.org/10.3390/v13050805.
Повний текст джерелаNuismer, Scott L., Benjamin M. Althouse, Ryan May, James J. Bull, Sean P. Stromberg, and Rustom Antia. "Eradicating infectious disease using weakly transmissible vaccines." Proceedings of the Royal Society B: Biological Sciences 283, no. 1841 (October 26, 2016): 20161903. http://dx.doi.org/10.1098/rspb.2016.1903.
Повний текст джерелаvan der Sanden, Sabine M. G., Weilin Wu, Naomi Dybdahl-Sissoko, William C. Weldon, Paula Brooks, Jason O'Donnell, Les P. Jones, et al. "Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game." Journal of Virology 90, no. 4 (November 18, 2015): 1694–704. http://dx.doi.org/10.1128/jvi.01464-15.
Повний текст джерелаOgonczyk Makowska, Daniela, Marie-Ève Hamelin, and Guy Boivin. "Engineering of Live Chimeric Vaccines against Human Metapneumovirus." Pathogens 9, no. 2 (February 19, 2020): 135. http://dx.doi.org/10.3390/pathogens9020135.
Повний текст джерелаVishweshwaraiah, Yashavantha L., and Nikolay V. Dokholyan. "Toward rational vaccine engineering." Advanced Drug Delivery Reviews 183 (April 2022): 114142. http://dx.doi.org/10.1016/j.addr.2022.114142.
Повний текст джерелаSudhakar, Poda, M. Usha Kiranmayi, Selvaraj Sankarpandian, Manyam Srinivasa Rao, M. Vijayalakshmi, and K. R. S. Sambasiva Rao. "Engineering generic vaccine vectors." International Journal of Biomedical Engineering and Technology 6, no. 1 (2011): 93. http://dx.doi.org/10.1504/ijbet.2011.040455.
Повний текст джерелаChoi, Ji Young, Bhushan Mahadik, and John P. Fisher. "3D printing technologies for in vitro vaccine testing platforms and vaccine delivery systems against infectious diseases." Essays in Biochemistry 65, no. 3 (August 2021): 519–31. http://dx.doi.org/10.1042/ebc20200105.
Повний текст джерелаTripp, Ralph, S. M. G. van der Sanden, W. Wu, N. dybdahl-Sissoko, William Weldon, P. Brooks, J. O'donnell, et al. "Engineering enhanced vaccine cell lines to eradicate vaccine preventable diseases: the polio endgame (VAC9P.1107)." Journal of Immunology 194, no. 1_Supplement (May 1, 2015): 145.15. http://dx.doi.org/10.4049/jimmunol.194.supp.145.15.
Повний текст джерелаДисертації з теми "Vaccine engineering"
Brune, Karl Dietrich. "Engineering modular platforms for rapid vaccine development." Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:41d57165-6e7c-4ca7-8025-b5ec31794c8c.
Повний текст джерелаHanes, Justin Scott. "Polymer microspheres for vaccine delivery." Thesis, Massachusetts Institute of Technology, 1996. http://hdl.handle.net/1721.1/10153.
Повний текст джерелаWebster, Gina. "Engineering immunoglobulin genes for novel Tuberculosis vaccine production in plants." Thesis, St George's, University of London, 2017. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.753991.
Повний текст джерелаKaczorowski, Kevin J. "Data-driven strategies for vaccine design." Thesis, Massachusetts Institute of Technology, 2017. http://hdl.handle.net/1721.1/117327.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references.
Vaccination is one of the greatest achievements in immunology and in general medicine, and has virtually eradicated many infectious diseases that plagued humans in the past. Vaccination involves injecting an individual with some version of the pathogen in order to allow the individual to develop a memory immune response that will protect them from future challenge with the same pathogen. Until recently, vaccine development has largely followed empirical paradigms that have proven successful against many diseases. However, many pathogens have now evolved that defy success using the traditional approaches. Rational design of vaccines against such pathogens will likely require interdisciplinary approaches spanning engineering, immunology, and the physical sciences. In this thesis, we combine theoretical approaches with protein sequence and clinical data to address two contemporary problems in vaccinology: 1. Developing an antibody vaccine against HIV, an example of a highly mutable pathogen; and 2. Understanding how the many immune components work collectively to effect a systemic immune response, such as to vaccines. In HIV-infected individuals, antibodies produced by the immune system bind to specific parts of an HIV protein called Envelope (Env). However, the virus evades the immune response due to its high mutability, thus making effective vaccine design a huge challenge. To predict the mutational vulnerabilities of the virus, we developed a model (a fitness landscape) to translate sequence data into knowledge of viral fitness, a measure of the ability of the virus to replicate and thrive. The landscape accounts explicitly for coupling interactions between mutations at different positions within the protein, which often dictate how the virus evades the immune response. We developed new computational approaches that enabled us to tackle the large size and mutational variability of Env, since previous approaches have been unsuccessful in this case. A small fraction of HIV-infected individuals produce a class of antibodies called broadly neutralizing antibodies (bnAbs), which neutralize a diverse number of HIV strains and can thus tolerate many mutations in Env. To investigate the mechanisms underlying breadth of these bnAbs, we combined our landscape with 3D protein structures to gain insight into the spatial distribution of binding interactions between bnAbs and Env. Based on this, we designed an optimal set of immunogens (i.e. Env sequences), with mutations at key residues, that are potentially likely to lead to the elicitation of bnAbs via vaccination. We hope that these antigens will soon be tested in animal models. Even when the right immunogens are included in a vaccine, a potent immune response is not always induced. For example, some individuals do not respond to protective influenza vaccines as desired. The human immune system consists of many different immune cells that coordinate their actions to fight infections and respond to vaccines. The balance between these cell populations is determined by direct interactions and soluble factors such as cytokines, which serve as messengers between cells. A mechanistic understanding of how the various immune components cooperate to bring about the immune response can guide strategies to improve vaccine efficacy. To investigate whether differences in immune response could be explained by variation in immune cell compositions across individuals, we analyzed experimental measurements of various immune cell population frequencies in a cohort of healthy humans. We demonstrated that human immune variation in these parameters is continuous rather than discrete. Furthermore, we showed that key combinations of these immune parameters can be used to predict immune response to diverse stimulations, namely cytokine stimulation and vaccination. Thus, we defined the concept of an individual's "immunotype" as their location within the space of these key combinations of parameters. This result highlights a previously unappreciated connection between immune cell composition and systemic immune responses, and can guide future development of therapies that aim to collectively, rather than independently, manipulate immune cell frequencies.
by Kevin J. Kaczorowski.
Ph. D.
DeMuth, Peter C. (Peter Charles). "Engineered microneedles for transcutaneous vaccine delivery." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/81667.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (p. 151-165).
Immunization is a powerful approach for the prevention and control of infectious disease, however despite the successes of modem vaccine development, there remain several notable obstacles for the advancement of vaccine-mediated improvements in global healthcare. Many of the current limitations in vaccine availability and administration are the result of obligate needle-based delivery, which in addition to contributing to reduced speed, ease, and compliance in administration, has been shown to contribute to reduced overall safety due to needle re-use and needle-based injuries. Needle-based vaccine delivery to immunologically passive tissues such as muscle may limit efficacy, thus motivating the targeting of more inherently potent immune-competent sites. These inherent limitations of needle-based vaccination on global health have led to a strong impetus to develop needle-free vaccination strategies which have the potential to improve vaccine efficacy and availability, enhance the ease, speed, and safety of vaccine administration, and reduce vaccination associated costs world-wide. Here we present the design and preclinical testing of several parallel materials strategies for the noninvasive delivery of subunit vaccines to the skin. We have utilized laser ablative micro-molding of poly(dimethylsiloxane) to generate bio resorbable poly(lactide-co-glycolide) micro-structured skin patches bearing -100 micron-scale needles arrayed across their surface. Upon topical application, these 'microneedle arrays' are able to safely, and painlessly insert into the immune-competent epidermal skin layers to generate microscopic conduits through which otherwise impermeant vaccines and therapeutics are able to passage into the body. We have leveraged this approach in combination with layer-by-layer (LbL) directed assembly to generate vaccine-loaded conformal coatings on the surface of these microneedle arrays, which are then delivered into the skin through topical patch application. The construction of coatings containing antigen-expressing plasmid DNA (pDNA), together with immune-stimulatory RNA, and degradable cationic polymers provided tunable control over vaccine dosage, rapid and effective vaccine delivery in murine and primate skin models, and potent immunogenicity against a model HIV antigen in mice. In this case, DNA vaccine delivery was able to elicit strong functional CD8' T cell and humoral responses matching or exceeding the potency of in vivo electroporation, currently the most promising approach for clinical DNA delivery in humans. Further efforts have explored the use of LbL for encapsulation and delivery of soluble and particulate protein subunit vaccines, giving enhanced generation of diverse and potent humoral responses in mice. In other work, we have developed an approach enabling rapid delivery of micron-scale degradable polymer matrices or hydrogel depots using dissolvable composite microneedle structures for the delivery of vaccines with programmable kinetics. These efforts have demonstrated the potential of persistent vaccine release on tuning immune potency following non-invasive microneedle delivery, including induction of potent effector and memory CD8* T cell responses and more powerful and diverse antigen-specific humoral responses. Finally, we have developed an approach for simple loading and delivery of clinically advanced recombinant adenoviral vaccine vectors from sugar-glass coatings on bioresorbable microneedles. Formulation in microneedle coatings improved vaccine stability at room temperature and preclinical testing of these vaccine patches in mice and nonhuman primates demonstrated equivalent immunogenicity compared to parenteral injection, eliciting strong systemic and disseminated mucosal CD8' and CD4* T cell responses to a model HIV antigen. These cellular responses were correlated with a similarly potent systemic and mucosal humoral response, together suggesting the utility of this approach for non-invasive adenoviral immunization in a model close to humans. Together these results strongly demonstrate the potential of materials engineering strategies for the effective formulation, delivery, and release of recombinant vaccines by microneedle patches targeting the skin. In addition to the significant practical advantages enabled by microneedle delivery including improved safety, convenience, and storage, we have shown that advanced formulation strategies paired with controlled release are able to initiate humoral and cellular adaptive immunity more potently than possible through parenteral injection. Comprehensive tests in both mice and primates have suggested that these principles may be broadly applied to enhance various recombinant vaccination strategies potentially targeting numerous disease targets. Finally, initial tests performed in nonhuman primates have indicated the promise of engineered microneedle approaches for successful translation to humans. Overall, these findings provide a strong basis for the continued development of similar vaccination strategies for the comprehensive transformation of conventional vaccination enabling significant vaccine-mediated improvements in global health.
by Peter C. DeMuth.
Ph.D.
Wikman, Maria. "Rational and combinatorial protein engineering for vaccine delivery and drug targeting." Doctoral thesis, Stockholm : Department of Biotechnology, Royal Insitute of Technology, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-231.
Повний текст джерелаHowland, Shanshan W. "Yeast-based vaccine approaches to cancer immunotherapy." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/45949.
Повний текст джерелаIncludes bibliographical references.
Saccharomyces cerevisiae stimulates dendritic cells and represents a promising candidate for cancer immunotherapy development. Effective cross-presentation of antigen delivered to dendritic cells is necessary for successful induction of cellular immunity. Using a yeast vaccine model, we investigated the phagosome-to-cytosol pathway of cross-presentation. We demonstrate that the rate of antigen release from phagocytosed yeast directly affects cross-presentation efficiency, with an apparent time limit of about 25 min post-phagocytosis for antigen release to be productive. Antigen expressed on the yeast surface is cross-presented much more efficiently than antigen trapped in the yeast cytosol by the cell wall. The cross-presentation efficiency of yeast surface-displayed antigen can be increased by the insertion of linkers susceptible to cleavage in the early phagosome. Antigens indirectly attached to yeast through antibody fragments are less efficiently cross-presented when the antibody dissociation rate is extremely slow. Next, we present a yeast-based cancer vaccine approach that is independent of yeast's ability to express the chosen antigen, which is instead produced separately and conjugated to the yeast cell wall. The conjugation method is site-specific (based on the SNAP-tag) and designed to facilitate antigen release in the dendritic cell phagosome and subsequent translocation for cross-presentation.
(cont.) Phagosomal antigen release was further expedited through the insertion of the invariant chain ectodomain as a linker, which is rapidly cleaved by Cathepsin S. The dose of delivered antigen was increased in several ways: by using yeast strains with higher surface amine densities, by using yeast cell wall fragments instead of whole cells, and by conjugating multiple layers of antigen. The novel multi-layer conjugation scheme is site-specific and takes advantage of Sfp phosphopantetheinyl transferase, enabling the antigen dose to grow linearly. We show that whole yeast cells coated with one layer of the cancer-testis antigen NY-ESO-1 and yeast hulls bearing three layers were able to cross-prime naive CD8+ T cells in vitro, with the latter resulting in higher frequencies of antigen-specific cells after ten days. This cross-presentation-efficient antigen conjugation scheme is not limited to yeast and can readily be applied towards the development of other particulate vaccines.
by Shanshan W. Howland.
Ph.D.
Chen, Hongming. "Polymerized liposomes as potential oral vaccine delivery vehicles." Thesis, Massachusetts Institute of Technology, 1996. http://hdl.handle.net/1721.1/10343.
Повний текст джерелаPanas, Cynthia Dawn Walker. "Design and manufacture of low cost vaccine cooler." Thesis, Massachusetts Institute of Technology, 2007. http://hdl.handle.net/1721.1/40937.
Повний текст джерелаIncludes bibliographical references (p. 58).
Vaccines are very sensitive to temperature, needing to be held between 2 and 80°C to maintain potency. In developing countries where electricity and fuel supplies are unreliable, many vaccines are ruined due to thermal exposure. These are also the locations where vaccines are needed the most, yet often many of the vaccines given are ineffective. Long holdover vaccine coolers are designed to maintain a proper internal temperature during long periods of power loss. The most prevalent technology is the ice-lined cooler, but in the field these often have problem with freezing the vaccines. A vaccine cooler was designed that modifies the ice-jacket idea by separating the ice compartment and the vaccine chamber, connecting them through a heat transfer regulating device. The objective of this research is to design and prototype the heat transfer regulating device. After several design iterations a cooling loop filled with R-134a made of 1/8 piping, a 0.055 in ID capillary, and a Clippard normally-closed valve was combined with a modified car thermostat, using peanut oil as its working fluid, to create a thermosyphon type heat transfer device with a safety shutoff to prevent freezing. The prototype was manufactured and tested. It was found that with the proper amount of working fluid, it is possible to run the cooling loop at 4°C and pull heat from the vaccine chamber side to the ice. The peanut oil thermostat was tested and was found to open at a slightly lower temperature than expected, 2.5°C, but still within range. These results indicate that the concept is viable and should be tested in the vaccine cooler.
by Cynthia D. Walker.
S.B.
Kang, Myungsun(Myungsun Sunny). "Optimizing vaccine dosing kinetics for stronger antibody response." Thesis, Massachusetts Institute of Technology, 2018. https://hdl.handle.net/1721.1/124586.
Повний текст джерелаCataloged from PDF version of thesis. "The pagination in this thesis reflects how it was delivered to the Institute Archives and Special Collections. The Table of Contents does not accurately represent the page numbering"--Disclaimer Notice page.
Includes bibliographical references (pages 95-102).
One of the barriers to rational vaccine design against evolving pathogens is our lack of mechanistic understanding of how innate and adaptive immune response systematically emerge and evolve. Immune response is comprised of dynamic events that require many components to cooperate collectively in a manner that spans a range of scales. These characteristics make it hard to predict mechanisms for immune response based solely on experimental observations. This thesis investigates various aspects of affinity maturation that are relevant to vaccination and therapeutic strategies but are not yet fully understood mechanistically, ranging from the evolution of the heterogeneity of the antibody population with respect to affinity to optimal design parameters for temporal dosing of vaccines. Our approach is to apply computational techniques to mathematically model the immune system, and being synergistic with complementary experiments. 1.
As affinity maturation ensues, average affinity of antibodies increase with time while resulting affinity distribution becomes increasingly heterogeneous. To shed light on how the extent of this heterogeneity evolves with time during affinity maturation, we have taken advantage of previously published data of antibodies isolated from individual serum samples. Using the ratio of the strongest to the weakest binding subsets as a metric of heterogeneity (or affinity inequality), we find that after a single injection of small antigen doses, the ratio decreases progressively over time. This is consistent with Darwinian evolution in the strong selection limit. By contrast, neither the average affinity nor the heterogeneity evolves much with time for high doses of antigen, as competition between clones of the same affinity is minimal. 2.
What are the aspects of affinity maturation being altered by various temporal patterns of antigen dosing? Certain extended-duration dosing profiles increase the strength of the humoral response, with exponentially-increasing(EI) dosage providing the greatest enhancement. While this is an exciting result, it is necessary to establish a mechanistic understanding of how immune response be enhanced to further engineer and optimize the temporal patterns. From our computational model, the effect is driven by enhanced capture of antigen in lymph nodes by evolving higher-affinity antibodies early in the GC response. We validate the prediction from independent experimental data, where EI dosage result in promoted capture and retention of the antigen in lymph nodes. To our knowledge, this work is the first to demonstrate a key mechanism for vaccine kinetics in the response of B cells to immunization, and may prove to be an effective method for increasing the efficacy of subunit vaccines. 3.
Are there optimal dosing profiles that maximize total protection? That is, lead to the evolution of the most antibodies of high affinity? In extension of mechanistic studies in 2, we propose a stochastic simulation method that can be used as a tool for optimizing dosage protocols for vaccine delivery. Using this tool, we analyze experimental conditions for EI dosage induce suboptimal immune response and investigate two approaches for the optimization. Specifically, reducing the total dosage optimizes affinity of resulting antibodies, while total protection is optimal neither at constant or EI dosage but that corresponding to a "linear-like" dosing profile. Our approach can be extended to broader applications in vaccine design.
by Myungsun (Sunny) Kang.
Ph. D.
Ph.D. Massachusetts Institute of Technology, Department of Chemical Engineering
Книги з теми "Vaccine engineering"
United States. Animal and Plant Health Inspection Service. Veterinary Services. Recombinant derived pseudorabies vaccine, TK: Environmental assessment and finding of no significant impact. Washington, D.C.?]: The Services, 1987.
Знайти повний текст джерелаButtram, Harold E. Are vaccines sowing seeds of genetic change? Quakertown, Pa: Philosohical Pub. Co., 2002.
Знайти повний текст джерелаV, Karasev Alexander, Malissen Bernard, Vogt, P. K. 1932- (Peter K.), Cooper Max D, Olsnes Sjur, Gleba Yuri Y, Honjō Tasuku, et al., eds. Plant-produced Microbial Vaccines. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009.
Знайти повний текст джерелаEdouard, Kurstak, ed. Modern vaccinology. New York: Plenum Medical Book Co., 1994.
Знайти повний текст джерелаThis cruel design. New York, NY: Simon Pulse, 2018.
Знайти повний текст джерелаCopyright Paperback Collection (Library of Congress), ed. The changeling plague. New York: Roc, 2003.
Знайти повний текст джерелаHo, Jason. Engineering an immunotargeting vaccine for type 1 human immunodeficiency virus. 2004.
Знайти повний текст джерелаMARROQUÍN-DE JESÚS, Ángel, Juan Manuel OLIVARES-RAMÍREZ, Marisela CRUZ-RAMÍREZ, and Luis Eduardo CRUZ-CARPIO. CIERMMI Women in Science Engineering and Technology TXV. ECORFAN, 2021. http://dx.doi.org/10.35429/h.2021.6.1.180.
Повний текст джерела(Editor), Fred Brown, and L. R. Haaheim (Editor), eds. Modulation of the Immune Response to Vaccine Antigens: Symposium, University of Bergen, June 1996, Developments in Biological Standardizati (Tissue Engineering). S. Karger Publishers (USA), 1998.
Знайти повний текст джерелаGenetically Engineered Vaccines. Springer, 2012.
Знайти повний текст джерелаЧастини книг з теми "Vaccine engineering"
Akache, Bassel, Felicity C. Stark, Gerard Agbayani, Tyler M. Renner, and Michael J. McCluskie. "Adjuvants: Engineering Protective Immune Responses in and Vaccines." In Vaccine Design, 179–231. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1892-9_9.
Повний текст джерелаZhu, Jingen, Neeti Ananthaswamy, Swati Jain, Himanshu Batra, Wei-Chun Tang, and Venigalla B. Rao. "CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against and Emerging Pathogens." In Vaccine Design, 209–28. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1884-4_10.
Повний текст джерелаDu, Ya-Fei, Ming Chen, Jia-Rui Xu, Qian Luo, and Wan-Liang Lu. "Preparation and Characterization of DNA Liposomes Vaccine." In Biomaterial Engineering, 1–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49231-4_20-1.
Повний текст джерелаDu, Ya-Fei, Ming Chen, Jia-Rui Xu, Qian Luo, and Wan-Liang Lu. "Preparation and Characterization of DNA Liposomes Vaccine." In Biomaterial Engineering, 259–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2021. http://dx.doi.org/10.1007/978-3-662-49320-5_20.
Повний текст джерелаHuang, Pei-Hua. "Uncertainty, Vaccination, and the Duties of Liberal States." In Philosophy of Engineering and Technology, 97–110. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08424-9_5.
Повний текст джерелаChauhan, Virander Singh, and Devesh Bhardwaj. "Current Status of Malaria Vaccine Development." In Advances in Biochemical Engineering/Biotechnology, 143–82. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/3-540-36488-9_5.
Повний текст джерелаBiswas, Saurabh, and Yasha Hasija. "Mucormycosis Vaccine Design using Bioinformatic Tools." In Lecture Notes in Electrical Engineering, 247–57. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-9885-9_21.
Повний текст джерелаNoe, W., R. Bux, W. Berthold, and W. Werz. "Optimization of vaccine production for animal health." In Cell Culture Engineering IV, 169–76. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-0257-5_19.
Повний текст джерелаKuai, Rui, Lukasz J. Ochyl, Anna Schwendeman, and James J. Moon. "Lipid-Based Nanoparticles for Vaccine Applications." In Biomedical Engineering: Frontier Research and Converging Technologies, 177–97. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-21813-7_8.
Повний текст джерелаShibasaki, Seiji. "Oral Vaccine Development Using Cell Surface Display Technology." In Yeast Cell Surface Engineering, 149–58. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-5868-5_11.
Повний текст джерелаТези доповідей конференцій з теми "Vaccine engineering"
Kumar, Vishnu, Vijay Srinivasan, and Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19." In ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.
Повний текст джерелаDevrani, Shitanshu, Sudhanshu Pandey, Shubham Chaturvedi, Krishnakumar Sankar, Shantanu Patil, and K. Sridhar. "Design and Analysis of an Efficient Vaccine Cold Chain Box." In ASME 2016 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/imece2016-65858.
Повний текст джерелаHasan, Shirin, Mir Mohammad Yousuf, Mubashir Farooq, Nishita Marwah, Syed Ahtisam Ashraf Andrabi, and Hemant Kumar. "e-Vaccine: An Immunization App." In 2021 2nd International Conference on Intelligent Engineering and Management (ICIEM). IEEE, 2021. http://dx.doi.org/10.1109/iciem51511.2021.9445386.
Повний текст джерелаJida Xing, Chenxia Hu, Allan Ma, Rajan George, James Z. Xing, and Jie Chen. "Pulsed ultrasound for enhancing vaccine production." In 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2015. http://dx.doi.org/10.1109/embc.2015.7318815.
Повний текст джерелаHe, Zijun, Mengshu He, and Emily Yuan. "Vaccine safety and efficacy: A literature review." In 3RD INTERNATIONAL CONFERENCE ON FRONTIERS OF BIOLOGICAL SCIENCES AND ENGINEERING (FBSE 2020). AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0049198.
Повний текст джерелаWu, Sijin, Hao Sun, Yancheng Lu, Susan Grant-Muller, and Lili Yang. "Initial COVID-19 Vaccine Distribution Policy Optimisation." In EBEE 2021: 2021 3rd International Conference on E-Business and E-commerce Engineering. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3510249.3510270.
Повний текст джерелаMan, Chun-tao, Gui-min Sheng, and Tao Zhang. "Adaptive Vaccine Extraction Immune Particle Swarm Optimization Algorithm." In 2009 2nd International Conference on Biomedical Engineering and Informatics. IEEE, 2009. http://dx.doi.org/10.1109/bmei.2009.5302919.
Повний текст джерелаRidzuan, Abdul Rauf, Hanita Hassan, Shafinar Ismail, S. Salahudin Suyurno, Yusa Dyujandi, Indra Prawira, and Mohd Hamzatul Akmar Md Zakaria. "Determinants of childhood vaccine rejection among Malaysian parents." In VIII INTERNATIONAL ANNUAL CONFERENCE “INDUSTRIAL TECHNOLOGIES AND ENGINEERING” (ICITE 2021). AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0119794.
Повний текст джерелаBaby Jerald, A., and T. R. Gopalakrishnan Nair. "Influenza virus vaccine efficacy based on conserved sequence alignment." In 2012 International Conference on Biomedical Engineering (ICoBE). IEEE, 2012. http://dx.doi.org/10.1109/icobe.2012.6179031.
Повний текст джерела"Evaluation of a Novel Adjuvant in Rabies Vaccine Formulation." In International Institute of Chemical, Biological & Environmental Engineering. International Institute of Chemical, Biological & Environmental Engineering, 2015. http://dx.doi.org/10.15242/iicbe.c0615084.
Повний текст джерелаЗвіти організацій з теми "Vaccine engineering"
Clements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Fort Belvoir, VA: Defense Technical Information Center, October 2012. http://dx.doi.org/10.21236/ada614939.
Повний текст джерелаClements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Fort Belvoir, VA: Defense Technical Information Center, February 2008. http://dx.doi.org/10.21236/ada482303.
Повний текст джерелаMuldrow, Lycurgus L., and Joe Johnson. Genetic Engineering of Clostridium Difficile Toxin A Vaccine. Fort Belvoir, VA: Defense Technical Information Center, September 1991. http://dx.doi.org/10.21236/ada242265.
Повний текст джерелаMuldrow, Lycurgus L., and Joe Johnson. Genetic Engineering of Clostridium Difficile Toxin a Vaccine. Fort Belvoir, VA: Defense Technical Information Center, August 1990. http://dx.doi.org/10.21236/ada230411.
Повний текст джерела